When: RSI >45 with lower Bollinger hold at $1,094 on >1M volume

Then: Alternative Tier-1 trigger activates; allows starter tranche if MACD gate has not fired

When: Price reaches $1,070-$1,090 zone with bullish reversal candle and >3M volume

Then: Tier-2 primary add becomes active at 200 SMA defense level

HOLD - Tighten stops on existing positions and wait for confirmed basing pattern with positive momentum divergence or deeper deration to 200 SMA support (~1,062) before adding capital

• 10 EMA peaked at 1,229 on August 25 and has been declining for 16 sessions with no curl signs
• Price below 10 EMA and 50 SMA for 16 consecutive sessions without a counter-trend bounce exceeding 3%
• 50 SMA has flattened and lost steep ascent indicating regime change in trend behavior
• Accelerating negative MACD histogram signals deteriorating, not improving, setup
• Beta of 0.50 measures correlation, not downside protection; does not shield from multiple derating
• PEG of 1.11 is reasonable only if capacity execution, pricing power, and demand growth all continue
• Forward P/E of 23.8x with 58% earnings growth consensus estimate questioned amid higher rates and competitive entry
• Net debt of 46 billion dollars with debt-to-equity of 162% creates real interest cost exposure in higher-for-longer rate environment
• Q2 capex of 6.2 billion dollars carries execution risk for multi-year capacity buildout
• 200 SMA support zone at 1,062 represents potential 15-20% additional drawdown from current levels (~1,123)
• Macro headwinds include PPI upside, multi-month yield highs, and sector contagion (e.g., Amgen down 10% from Novartis pelacarsen flop)
• Political GLP-1 risks include Medicare negotiation expansion, PBM reform, and Congressional drug pricing scrutiny
• Competitive risks from Novo Nordisk, Viking, and oral GLP-1 entrants

→ vs aggressive: The '5-to-1 reward-to-risk' assumes an arbitrary stop loss that may not hold; real downside risk if 200 SMA breaks is 15-20% additional drawdown potentially extending to 950

→ vs aggressive: Low beta (0.50) does not provide downside protection during idiosyncratic multiple compression; in sustained rotation out of long-duration growth, even low-beta names can lose 20%

→ vs aggressive: Beta measures correlation to broader market, not downside protection in idiosyncratic events or fundamental breaks

→ vs aggressive: The 'wait for basing is performance anxiety' framing is backwards; waiting for confirmation is evidence-based discipline, not capitulation to fear

→ vs aggressive: If buy at 1,124 and basing signal comes at 1,062, that's a 5.5% loss from early entry; disciplined waiting avoids this known risk

→ vs aggressive: Dismissal of bear case as 'valuation anxiety from people who missed the move' is intellectually lazy; the bear case includes deteriorating technicals, hostile macro, sector contagion, and political risk

→ vs aggressive: A stock can have a beta of 0.50 and still be cut in half if its own fundamentals break or multiple compresses

→ vs aggressive: The company has levered up aggressively (162% D/E) to fund capacity and M&A; interest expense will grow in higher-for-longer environment

→ vs aggressive: M&A pipeline (Morphic acquisition, Caspian investment) requires integration discipline not guaranteed

→ vs aggressive: Calling 12% decline 'the setup is improving' while MACD histogram accelerates negative is contradicted by the technical evidence itself

HOLD with active tiered scale-in deployment plan; tighten existing stop to close below 1,094; no additions above 1,151; pre-commit to three-tranche scale-in at 1,094-1,100, on confirmed basing, and at 1,061-1,062 on capitulation

• Orderly grinding lower is not the same as orderly accumulation; institutions can distribute quietly without panic being visible
• Beta measures correlation to market beta, not protection from idiosyncratic multiple compression; a 0.50 beta stock can lose 25% in a multiple compression regime while market is flat
• The aggressive analyst's 5-to-1 reward-to-risk claim requires two unproven assumptions: 200 SMA holds and upside target of 1,280 to 1,350 gets realized
• If 200 SMA breaks on closing basis, next support is 950 to 1,000 zone, representing 15 to 20% further drawdown from current levels
• Conservative analyst treats medium-term technical chart as leading indicator of long-term outcomes, which is backwards
• 12% decline from 1,280 to 1,123 is natural digestion of a 56% one-year rally
• 162% debt-to-equity and $46B net debt is appropriate for a pharma self-funding $11B in annual free cash flow with 50%+ growth
• Cleanest basing signals in quality compounders often form AFTER price has moved 8 to 12% higher from the actual low
• Macro environment (hot PPI, surging yields, 8% probability of December cut, tax-loss harvesting season) argues for capital preservation
• Deploying capital at 1,094 with stop at 1,025 targeting 1,200 represents a 2.6-to-1 reward-to-risk with structural thesis
• Adding 5.6% of portfolio risk to chase 14% upside when already has exposure is poor risk-adjusted trade in current environment
• First tranche should be small position (one-third of intended size) at 1,094 to 1,100 near Bollinger lower band with tight stop below 200 SMA at 1,061
• Second tranche (one-third of position size) requires RSI divergence, MACD flattening, and price holding 10 EMA for at least three sessions
• Third tranche reserved for deeper derating to 200 SMA with capitulation volume where asymmetric risk-reward truly materializes
• Break of 1,094 on closing basis would be meaningful warning of trend change, not healthy consolidation

→ vs aggressive: Orderly grinding argument has logical hole; orderly distribution can look exactly like orderly accumulation, institutions can trim quietly without panic being visible, and absence of panic candle doesn't prove accumulation

→ vs aggressive: Beta argument weaker than presented; beta measures market correlation not protection from multiple compression, a 0.50 beta stock can lose 25% in a multiple compression regime while market is flat

→ vs aggressive: 5-to-1 reward-to-risk claim is not truly 5-to-1 once realistic downside is factored in; if 200 SMA breaks, next support is 950 to 1,000, making it more like 3-to-1 with significant tail risk

→ vs aggressive: Argument essentially boils down to 'trust thesis more than price action,' which is dangerous; when fundamentals and price action diverge, that's information, not anxiety

→ vs conservative: Treats technical deterioration as verdict rather than data point; 16 sessions without 3% bounce is concerning but must be put in context of 12% decline digesting 56% rally

→ vs conservative: Leverage framing overstated; 162% debt-to-equity is appropriate for a capex-and-M&A growth posture funded by own cash flow, not a distressed balance sheet

→ vs conservative: Framing has hidden assumption that basing signal will be obvious; cleanest basing signals often form after price has already moved 8 to 12% higher from actual low